The combination therapy of PEG-IFN alpha 2b, Ribavirin and Telaprevir for the patients with chronic hepatitis C:the study for treatment duration by response guided therapy and prediction of efficacy by gene analysis in Japan.
Not Applicable
- Conditions
- chronic hepatitis C
- Registration Number
- JPRN-UMIN000018971
- Lead Sponsor
- agoya university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
1.patients contraindication for telaprevir 2)patients with rush by telaprevir 3)patients who used contraindication drugs with telaprevir 4)pregnacy 5)pregnacy for partener 6)partner can not understand contraception 7)allergy for RBV 8)sevre heart disease 9)salasemia 10)sevre renal disease 11)mental desease 12)sevre liver disease 13)AIH 14)contraindication for PEG-IFN-2b 15)allergy for vaccine 16)shosaikoto user 17)plick test positive 18) a.Hb>12g/dl b. nuet>1,500/mm3 c.platetlet>100,000/mm3 19)past use of telaprevir 20)active infecious desisease 21)cancer 22)contraindication by doctor in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SVR rate
- Secondary Outcome Measures
Name Time Method